This trial investigates how well short course radiation therapy works after surgery in treating patients with endometrial cancer who are receiving or have received chemotherapy. Short course (hypofractionated) radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects compared to standard radiation therapy.
Additional locations may be listed on ClinicalTrials.gov for NCT04386993.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVE:
I. To prospectively evaluate hematologic, gastrointestinal (GI), and genitourinary (GU) toxicity from ultra-hypofractionated radiation to the pelvis after hysterectomy for endometrial cancer.
SECONDARY OBJECTIVES:
I. To evaluate the effect of ultra-hypofractionated radiation to the pelvis after hysterectomy on urinary toxicity and GI toxicity.
II. To assess quality of life before and after ultra-hypofractionated radiation to the pelvis after hysterectomy.
III. To determine the disease response to ultra-hypofractionated radiation to the pelvis after hysterectomy.
OUTLINE:
After completion of standard of care hysterectomy, patients undergo ultra-hypofractionated intensity-modulated radiation therapy (IMRT) daily over 1-2 weeks for a total of 5 fractions.
After completion of study treatment, patients are followed up at 2 weeks, and at 3, 6, and 12 months.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationSiteman Cancer Center at Washington University
Principal InvestigatorJessika Contreras
